Compare STRIDES PHARMA SCIENCE with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs AUROBINDO PHARMA - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE AUROBINDO PHARMA STRIDES PHARMA SCIENCE/
AUROBINDO PHARMA
 
P/E (TTM) x 14.4 10.9 131.8% View Chart
P/BV x 0.9 2.4 35.8% View Chart
Dividend Yield % 0.6 0.5 108.3%  

Financials

 STRIDES PHARMA SCIENCE   AUROBINDO PHARMA
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
AUROBINDO PHARMA
Mar-18
STRIDES PHARMA SCIENCE/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,147809 141.8%   
Low Rs642504 127.4%   
Sales per share (Unadj.) Rs317.2281.1 112.9%  
Earnings per share (Unadj.) Rs7.841.4 19.0%  
Cash flow per share (Unadj.) Rs25.150.9 49.2%  
Dividends per share (Unadj.) Rs2.002.50 80.0%  
Dividend yield (eoy) %0.20.4 58.7%  
Book value per share (Unadj.) Rs274.3199.4 137.6%  
Shares outstanding (eoy) m89.50585.88 15.3%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.82.3 120.7%   
Avg P/E ratio x114.015.9 718.3%  
P/CF ratio (eoy) x35.712.9 276.7%  
Price / Book Value ratio x3.33.3 99.0%  
Dividend payout %25.56.0 421.7%   
Avg Mkt Cap Rs m80,058384,630 20.8%   
No. of employees `0002.517.3 14.5%   
Total wages/salary Rs m4,34121,308 20.4%   
Avg. sales/employee Rs Th11,325.89,500.7 119.2%   
Avg. wages/employee Rs Th1,731.41,229.4 140.8%   
Avg. net profit/employee Rs Th280.11,397.9 20.0%   
INCOME DATA
Net Sales Rs m28,394164,666 17.2%  
Other income Rs m9411,020 92.2%   
Total revenues Rs m29,334165,686 17.7%   
Gross profit Rs m3,96537,718 10.5%  
Depreciation Rs m1,5405,580 27.6%   
Interest Rs m1,962777 252.5%   
Profit before tax Rs m1,40332,380 4.3%   
Minority Interest Rs m031 0.0%   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-4360-   
Tax Rs m978,183 1.2%   
Profit after tax Rs m70224,229 2.9%  
Gross profit margin %14.022.9 61.0%  
Effective tax rate %6.925.3 27.4%   
Net profit margin %2.514.7 16.8%  
BALANCE SHEET DATA
Current assets Rs m24,836121,878 20.4%   
Current liabilities Rs m18,99386,806 21.9%   
Net working cap to sales %20.621.3 96.6%  
Current ratio x1.31.4 93.1%  
Inventory Days Days71130 54.6%  
Debtors Days Days11368 165.9%  
Net fixed assets Rs m34,28981,037 42.3%   
Share capital Rs m895586 152.8%   
"Free" reserves Rs m23,651116,218 20.4%   
Net worth Rs m24,546116,804 21.0%   
Long term debt Rs m15,5134,512 343.8%   
Total assets Rs m65,437211,052 31.0%  
Interest coverage x1.742.7 4.0%   
Debt to equity ratio x0.60 1,636.1%  
Sales to assets ratio x0.40.8 55.6%   
Return on assets %4.111.8 34.4%  
Return on equity %2.920.7 13.8%  
Return on capital %6.927.4 25.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,69780,727 19.4%   
Fx outflow Rs m73534,700 2.1%   
Net fx Rs m14,96246,027 32.5%   
CASH FLOW
From Operations Rs m1,87119,548 9.6%  
From Investments Rs m5,826-19,570 -29.8%  
From Financial Activity Rs m-10,1578,642 -117.5%  
Net Cashflow Rs m-2,6158,922 -29.3%  

Share Holding

Indian Promoters % 27.7 54.1 51.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 8.0 475.5%  
FIIs % 8.6 27.7 31.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 10.2 253.9%  
Shareholders   56,241 69,601 80.8%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   CADILA HEALTHCARE  TTK HEALTHCARE  ORCHID PHARMA LTD  BIOCON   J.B.CHEMICALS  

Compare STRIDES PHARMA SCIENCE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; Telecom and Automobiles Stocks Lose(09:30 am)

Asian share markets are lower today as Chinese and Hong Kong shares fall. The Shanghai Composite is off 0.1% while the Hang Seng is down 0.1%.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Oct 18, 2019 09:59 AM

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE - CIPLA COMPARISON

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS